NOVATO, Calif., Jan. 11, 2011 /PRNewswire/ — BioMarin
Pharmaceutical Inc. (Nasdaq:
BMRN) today announced the initiation of a Phase 1/2 trial for
BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in
development for the treatment of genetically-defined cancers.
“PARP inihibtors have been validated to show survival benefits
in cancer patients with tumors that have defects in DNA repair or
in combination with DNA damaging agents, and BMN 673 appears to
have superior potency, selectivity, and bioavailability as compared
to other products in development,” said Hank Fuchs, Chief Medical
Officer of BioMarin. “There are many possible targets for
PARP inhibitors, and we hope to identify which cancers are more
susceptible to treatment with BMN 673 in the Phase 1/2 trial.
We remain intently focused on developing our R&D pipeline
and look forward to many clinical milestones in the coming
year.”
The Phase 1/2 trial is an open-label study of once daily, orally
administered BMN 673 in approximately 70 patients ages 18 and older
with advanced or recurrent solid tumors. The primary
objective of the study is to establish the maximum tolerated dose
of daily oral BMN 673. The secondary objectives are to assess
the safety, tolerability, preliminary efficacy and phatrmacodynamic
activity of BMN 673, and to determine the pharmacokinetic profile
and recommended Phase 2 dose.
About BioMarinBioMarin develops and commercializes innovative
biopharmaceuticals for serious diseases and medical conditions. The
company’s product portfolio comprises four approved products and
multiple clinical and pre-clinical product candidates. Approved
products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for
mucopolysaccharidosis I (MPS I), a produ
‘/>”/>
SOURCE